BELGRADE, SERBIA, March 23 /PRNewswire-FirstCall/ - Slavica Biochem
(http://www.slavicabiochem.com), registered subsidiary of Hard to
Treat Diseases (http://www.htdsmedical.com), has released its RD
(research and development) expenditures for 2009.
The List comprises of expenses connected with the purchase of
laboratory equipment, travel and other miscellaneous expenses
necessary for the operation, cooperation and coordination of
Slavica BioChem's business and research. As HTDS does not subscribe
to Pink Sheets filing service. The company followers may review
this exhausting list of expenditures on the company IR web site
'Filings and News' section. See "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/
Slavica BioChem also continues its commitment to a development
of its own division devoted to Regenerative medicine.
Regenerative Medicine is the process of creating living,
functional tissues to repair or replace tissue or organ function
lost due to age, disease, damage, or congenital defects. This field
holds the promise of regenerating damaged tissues and organs in the
body by stimulating previously irreparable organs to heal
themselves.
Scientific research is working to make treatments available for
clinical use. Treatments include both in vivo and in vitro
procedures. In vivo meaning studies and trials performed inside the
living body in order to stimulate previously irreparable organs to
heal themselves. In vitro treatments are applied to the body
through implantation of a therapy studied inside the
laboratory.
The company will advise the shareholders on all developments in
timely manner.
The company reminds its shareholders and followers to our IR
company web site section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful
that short sellers, the company competitors and stock bashers stalk
small cap Pink Sheets listed companies with hidden agendas. Visit
http://www.stockbasher.com/ and find out what criminal and civil
actions the US authorities are taking against web sites like
investorshub.com and other posters, and the remedies available to
you as an individual investor.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases